Yes, LP, LG and the lot could agree not hold all options and warrants for a period of time which would de-risk the over-allotment. It would allow time to make whatever deal they are exploring. IMO, going it alone would be a LP ego play and not a benefit to GBM patients. There is no scenario where I see the treatment getting to patients faster going it alone. Partnerships are a possibility, but again, a longer road and less value to shareholders, IMO. A buyout is the best for patients and shareholders, IMO. And the "comments" from DI stating they are working towards the best outcome for patients and shareholders points me in the buyout direction.
Market Data 
Markets 
AI
